All In Biotech

Drug Trial Radar · NCT07219602

A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome

A Placebo-Controlled, Double-Blind, Randomized, Phase 3 Study to Evaluate the Effect of Obicetrapib 10 mg and Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome (RUBENS Trial)

Last checked: Nov 19, 2026Latest source record: Sep 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 300 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

300

Planned (sponsor's estimate)

Start

Dec 11, 2025

Primary completion

Mar 2028

Study completion Jun 2028

Sponsor

Lead sponsor
NewAmsterdam PharmaIndustry
Sponsor type
Industry
First posted
Oct 22, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will be a placebo-controlled, double-blind, randomized, Phase 3 study to evaluate the efficacy, safety, and tolerability of obicetrapib 10 mg, both as a fixed-dose combination (FDC) with ezetimibe 10 mg and as monotherapy, on top of guideline-recommended lipid-lowering therapy in patients with metabolic syndrome and/or Type 2 Diabetes Mellitus.

Conditions

  • Lipidemia
  • Type 2 Diabetes (T2DM)
  • Metabolic Syndrome (MetS)

Interventions

  • obicetrapib 10 mg + ezetimibe 10 mg FDC dailyDrug

    FDC

  • Obicetrapib 10 mgDrug

    monotherapy

  • PlaceboOther

    placebo on top of guideline-recommended lipid modifying therapy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The percent change from Baseline to Day 84 in LDL-C compared with placebo for the following treatment groups: - obicetrapib 10 mg + ezetimibe 10 mg FDC treatment group; and - obicetrapib 10 mg monotherapy treatment groupTime frame: 84 days

Locations

55 sites in 4 countries. Site status is shown where the registry gives one.

  • Clinical Research Institute of Arizona

    Sun City West, Arizona

  • Scripps Health - Whittier Diabetes Institute

    La Jolla, California

  • UC SanDiego Health

    La Jolla, California

  • Western University of Health Sciences

    Pomona, California

  • UF Health Jackson

    Jacksonville, Florida

  • East Coast Institute of Research LLC

    Jacksonville, Florida

  • East Coast Institute of Research LLC

    Lake City, Florida

  • K2 Medical Research

    Maitland, Florida

  • Floridian Clinical Research

    Miami Lakes, Florida

  • Cardiovascular Center of Sarasote Foundation for Research and Education

    Sarasota, Florida

  • High Desert Heart

    Meridian, Idaho

  • Endeavour Health

    Skokie, Illinois

  • Louisville Metabolic and Atherosclerosis Research Center (L-MARC)

    Louisville, Kentucky

  • Eastern Maine Medical Center

    Bangor, Maine

  • MD Medical Research

    Oxon Hill, Maryland

  • Jefferson City Medical Group

    Jefferson City, Missouri

  • Montana Medical Research

    Missoula, Montana

  • Inspira Health - Internal Medicine Associates

    Bridgeton, New Jersey

  • Central New York Clinical Research

    Manlius, New York

  • Duke University Medical Center

    Durham, North Carolina

  • Velocity Clinical Research

    Durham, North Carolina

  • PharmQuest Life Sciences, LLC

    Greensboro, North Carolina

  • Centricity Research dba Lucas Research

    Morehead City, North Carolina

  • Summit Research Group

    Munroe Falls, Ohio

  • Diabetes & Glandular Disease Clinic, P.A.

    Kingsport, Tennessee

  • Baylor College of Medicine - Center for Cardiometabolic Disease Prevention (The Center for Cardiovascular Disease Prevention)

    Houston, Texas

  • Juno Research LLC - Medical Center

    Houston, Texas

  • PlanIt Research, PLLC

    Houston, Texas

  • Clinical Trials of Texas dba Flourish Research

    San Antonio, Texas

  • Burke Internal Medicine

    Burke, Virginia

  • Burke International Medicine DBA Manassas Clinical Research Center

    Manassas, Virginia

  • Universal Research Group

    Tacoma, Washington

  • DOCTOR MN s.r.o

    Čáslav, Czechia

  • MUDr. Alena Váchová

    České Budějovice, Czechia

  • MEDIKA Hradec Králové, s.r.o.

    Hradec Králové, Czechia

  • Interni diabetologicka ambulance (Pratia)

    Jílové u Prahy, Czechia

  • Diabetologie - Dr. Tomas Edelsberger

    Krnov, Czechia

  • Pratia Pardubice a.s. (Pratia)

    Pardubice, Czechia

  • Dieko s.r.o

    Pilsen, Czechia

  • Nemocnice Na Františku

    Prague, Czechia

Showing 40 of 55 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.